These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 18537222)

  • 1. Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone.
    Suzuki T; Uchida H; Watanabe K; Nakajima S; Nomura K; Takeuchi H; Tanabe A; Yagi G; Kashima H
    Hum Psychopharmacol; 2008 Aug; 23(6):455-63. PubMed ID: 18537222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.
    Suzuki T; Uchida H; Watanabe K; Nomura K; Takeuchi H; Tomita M; Tsunoda K; Nio S; Den R; Manki H; Tanabe A; Yagi G; Kashima H
    Psychopharmacology (Berl); 2007 Dec; 195(2):285-95. PubMed ID: 17701027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics.
    Faries D; Ascher-Svanum H; Zhu B; Correll C; Kane J
    BMC Psychiatry; 2005 May; 5():26. PubMed ID: 15921508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipsychotic monotherapy and polypharmacy in the treatment of outpatients with schizophrenia in the European Schizophrenia Outpatient Health Outcomes Study.
    Novick D; Ascher-Svanum H; Brugnoli R; Bertsch J; Hong J; Haro JM
    J Nerv Ment Dis; 2012 Jul; 200(7):637-43. PubMed ID: 22759944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipsychotic switching: results from a one-year prospective, observational study of patients with schizophrenia.
    Karagianis J; Williams R; Davis L; Procyshyn R; Monga N; Hanley J; Chandrasena R; Thakur A; Dickson R
    Curr Med Res Opin; 2009 Sep; 25(9):2121-32. PubMed ID: 19601707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S; Agoston T; Tamás T; Zoltán J
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost of antipsychotic polypharmacy in the treatment of schizophrenia.
    Zhu B; Ascher-Svanum H; Faries DE; Correll CU; Kane JM
    BMC Psychiatry; 2008 Apr; 8():19. PubMed ID: 18394168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.
    McEvoy JP; Lieberman JA; Stroup TS; Davis SM; Meltzer HY; Rosenheck RA; Swartz MS; Perkins DO; Keefe RS; Davis CE; Severe J; Hsiao JK;
    Am J Psychiatry; 2006 Apr; 163(4):600-10. PubMed ID: 16585434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis.
    Agid O; Arenovich T; Sajeev G; Zipursky RB; Kapur S; Foussias G; Remington G
    J Clin Psychiatry; 2011 Nov; 72(11):1439-44. PubMed ID: 21457676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
    Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
    J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine.
    Byerly MJ; Nakonezny PA; Bettcher BM; Carmody T; Fisher R; Rush AJ
    Schizophr Res; 2006 Sep; 86(1-3):244-50. PubMed ID: 16730951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.
    Mladsi DM; Grogg AL; Irish WD; Lopez RB; Degen K; Swann A; Nimsch CT
    Curr Med Res Opin; 2004 Dec; 20(12):1883-93. PubMed ID: 15701206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial.
    Sacchetti E; Valsecchi P; Parrinello G;
    Schizophr Res; 2008 Jan; 98(1-3):55-65. PubMed ID: 17933497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of changing from typical to atypical antipsychotic drugs on subjective sleep quality in patients with schizophrenia in a Japanese population.
    Yamashita H; Mori K; Nagao M; Okamoto Y; Morinobu S; Yamawaki S
    J Clin Psychiatry; 2004 Nov; 65(11):1525-30. PubMed ID: 15554767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia.
    Faries DE; Ascher-Svanum H; Nyhuis AW; Kinon BJ
    Curr Med Res Opin; 2008 May; 24(5):1399-405. PubMed ID: 18397549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
    Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Capuano GA; Rosenheck RA; Keefe RS; Miller AL; Belz I; Hsiao JK;
    Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone.
    Larmo I; de Nayer A; Windhager E; Lindenbauer B; Rittmannsberger H; Platz T; Jones AM; Altman C;
    Hum Psychopharmacol; 2005 Dec; 20(8):573-81. PubMed ID: 16175656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of depressive symptoms in patients with schizophrenia: a randomized, open-label, parallel-group, flexible-dose subgroup analysis of patients treated with extended-release quetiapine fumarate or risperidone.
    Kasper S; Montagnani G; Trespi G; Di Fiorino M
    Int Clin Psychopharmacol; 2015 Jan; 30(1):14-22. PubMed ID: 25356632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial.
    Ciudad A; Olivares JM; Bousoño M; Gómez JC; Alvarez E
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Dec; 30(8):1515-22. PubMed ID: 16820255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of risperidone and olanzapine as used under "real-world" conditions in a state psychiatric hospital.
    Advokat C; Dixon D; Schneider J; Comaty JE
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 May; 28(3):487-95. PubMed ID: 15093956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.